인쇄하기
취소
|
Foreign expansion of Korean competitive biomedicines is going to be active.
The leading biosimilar companies are Celltrion and Samsung Bioepis. The two companies gave notices of the launch of the autoimmune treatment, ‘Remicade,’ to the European and U.S. markets, the largest biosimilar markets.
Recently, in addition, SK Chemicals acquired the final commercialization approval of Afstyla, a hem...